

Current State of Lung Cancer 2024: 4th Annual ELCN Gathering

Nasser Hanna, MD Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research Founder and Chairperson, ELCN Chief, Cancer Screenings, IU Health



Lung cancer related deaths in the U.S

Decade	Deaths in Women	Deaths in Men	Deaths men & Women
1930s	14,724	33,715	48,439
1940s	28,087	94,325	122,412
1950s	55,750	220,282	276,032
1960s	77,505	404,780	482,285
1970s	185,775	630,002	815,777
1980s	334,558	830,655	1,165,213
1990s	579,069	917,445	1,496,514
2000s	684,174	894,825	1,578,999
2021s	688,911	826,325	1,515,236
2020-present	306,640 and counting	346,268 and counting	652,908 and counting





Lung cancer related deaths in the U.S

Decade	Deaths in Women	Deaths in Men	Deaths men & Women				
1930s	14,724	33,715	48,439				
1940s	28,087	94,325	122,412				
1950s Over	1950s Over 8 million deaths, including 5 million						
1960s	men and 3	million wome	n				
1970s	185,775	630,002	815,777				
1980s	334,558	830,655	1,165,213				
1990s	579,069	917,445	1,496,514				
2000s	684,174	894,825	1,578,999				
2021s	688,911	826,325	1,515,236				
2020-present	306,640 and counting	346,268 and counting	652,908 and counting				





Lung cancer related deaths in the U.S

Decade	Deaths in Women	Deaths in Men	Deaths men & Women					
1930s	14,724	33,715	48,439					
1940s	28,087	94,325	122,412					
1950s Over	1950s Over 8 million deaths, including 5 million							
1960s	men and 3	3 million wome	n					
1970s	185 775	630 002	815 777					
	65,790 more men and 59,280 more women have died due to lung cancer since last year's ELCN Gathering							
1990s	579,069	917,445	1,496,514					
2000s	684,174	894,825	1,578,999					
2021s	688,911	826,325	1,515,236					
2020-present	306,640 and counting	346,268 and counting	652,908 and counting					



Cancer statistics, 2024

	Male				Female		
	Prostate	299,010	29%		Breast	310,720	32%
es	Lung & bronchus	116,310	11%	7 1	Lung & bronchus	118,270	12%
	Colon & rectum	81,540	8%	A 7	Colon & rectum	71,270	7%
Estimated New Cases	Urinary bladder	63,070	6%		Uterine corpus	67,880	7%
>	Melanoma of the skin	59,170	6%		Melanoma of the skin	41,470	4%
ž	Kidney & renal pelvis	52,380	5%		Non-Hodgkin lymphoma	36,030	4%
ted	Non-Hodgkin lymphoma	44,590	4%		Pancreas	31,910	3%
nat	Oral cavity & pharynx	41,510	4%		Thyroid	31,520	3%
Sti.	Leukemia	36,450	4%		Kidney & renal pelvis	29,230	3%
ш	Pancreas	34,530	3%		Leukemia	26,320	3%
	All sites	1,029,080			All sites	972,060	
	Male				Female		
	Lung & bronchus	65,790	20%		Lung & bronchus	59,280	21%
	Prostate	35,250	11%	7 1	Breast	42,250	15%
	Colon & rectum	28,700	9%	A 7	Pancreas	24,480	8%
£	Pancreas	27,270	8%		Colon & rectum	24,310	8%
)ea	Liver & intrahepatic bile duct	19,120	6%		Uterine corpus	13,250	5%
ē	Leukemia	13,640	4%		Ovary	12,740	4%
ate	Esophagus	12,880	4%		Liver & intrahepatic bile duct	10,720	4%
Estimated Deaths	Urinary bladder	12,290	4%		Leukemia	10,030	3%
E	Non-Hodgkin lymphoma	11,780	4%		Non-Hodgkin lymphoma	8,360	3%
	Brain & other nervous system	10,690	3%		Brain & other nervous system	8,070	3%
	All sites	322,800			All sites	288,920	

Estimates are rounded to the nearest 10, and cases exclude basal cell and squamous cell skin cancers and in situ carcinoma except urinary bladder. Estimates do not include Puerto Rico or other US territories. Ranking is based on modeled projections and may differ from the most recent observed data.


©2024, American Cancer Society, Inc., Surveillance and Health Equity Science

CA A Cancer J Clinicians, Volume: 74, Issue: 1, Pages: 12-49, First published: 17 January 2024, DOI: (10.3322/caac.21820)



Cancer statistics, 2024

	Male				Female		
	Prostate	299,010	29%		Breast	310,720	32%
	Lung & bronchus	116,310	11%	7 8	Lung & bronchus	118,270	12%
ses	Colon & rectum	81,540	8%	AI	Colon & rectum	71,270	7%
Estimated New Cases	Urinary bladder	63,070	6%		Uterine corpus	67,880	7%
>	Melanoma of the skin	59,170	6%		Melanoma of the skin	41,470	4%
ž	Kidney & renal pelvis	52,380	5%		Non-Hodgkin lymphoma	36,030	4%
ted	Non-Hodgkin lymphoma	44,590	4%		Pancreas	31,910	3%
Па	Oral cavity & pharynx	41,510	4%		Thyroid	31,520	3%
痣	Leukemia	36,450	4%		Kidney & renal pelvis	29,230	3%
ш	Pancreas	34,530	3%		Leukemia	26,320	3%
	All sites	1,029,080			All sites	972,060	
	Male				Female		
	Male Lung & bronchus	65,790	20%		Female Lung & bronchus	59,280	21%
		65,790 35,250	20% 11%			59,280 42,250	21% 15%
	Lung & bronchus			1 :	Lung & bronchus	,	
ıths	Lung & bronchus Prostate	35,250	11%	1 :	Lung & bronchus Breast	42,250	15%
Deaths	Lung & bronchus Prostate Colon & rectum	35,250 28,700	11% 9%	1 1	Lung & bronchus Breast Pancreas	42,250 24,480	15% 8%
ed Deaths	Lung & bronchus Prostate Colon & rectum Pancreas	35,250 28,700 27,270	11% 9% 8%	ii	Lung & bronchus Breast Pancreas Colon & rectum	42,250 24,480 24,310	15% 8% 8%
ated Deaths	Lung & bronchus Prostate Colon & rectum Pancreas Liver & intrahepatic bile duct	35,250 28,700 27,270 19,120	11% 9% 8% 6%	ii	Lung & bronchus Breast Pancreas Colon & rectum Uterine corpus	42,250 24,480 24,310 13,250	15% 8% 8% 5%
timated Deaths	Lung & bronchus Prostate Colon & rectum Pancreas Liver & intrahepatic bile duct Leukemia	35,250 28,700 27,270 19,120 13,640	11% 9% 8% 6% 4%	ii	Lung & bronchus Breast Pancreas Colon & rectum Uterine corpus Ovary	42,250 24,480 24,310 13,250 12,740	15% 8% 8% 5% 4%
Estimated Deaths	Lung & bronchus Prostate Colon & rectum Pancreas Liver & intrahepatic bile duct Leukemia Esophagus	35,250 28,700 27,270 19,120 13,640 12,880	11% 9% 8% 6% 4% 4%	ij	Lung & bronchus Breast Pancreas Colon & rectum Uterine corpus Ovary Liver & intrahepatic bile duct	42,250 24,480 24,310 13,250 12,740 10,720	15% 8% 8% 5% 4% 4%
Estimated Deaths	Lung & bronchus Prostate Colon & rectum Pancreas Liver & intrahepatic bile duct Leukemia Esophagus Urinary bladder	35,250 28,700 27,270 19,120 13,640 12,880 12,290	11% 9% 8% 6% 4% 4%	ij	Lung & bronchus Breast Pancreas Colon & rectum Uterine corpus Ovary Liver & intrahepatic bile duct Leukemia	42,250 24,480 24,310 13,250 12,740 10,720 10,030	15% 8% 8% 5% 4% 4% 3%



@2024, American Cancer Society, Inc., Surveillance and Health Equity Science

2nd most common cancer in men and women

Leading cause of cancer-death in men and women

In 2024, more women were diagnosed with lung cancer than men





Lung cancer cases by state: 2024


- Indiana ranks # 6 amongst men and # 5 amongst women in incidence
 - 5,930 new cases
- Indiana ranks # 8 amongst men and #8 amongst women in death
 - 3,390 deaths



Cigarette consumption is declining across all groups in the U.S.







AAPI: Asian American and Pacific Islander individuals; AIAN: American Indian and Alaska Native individuals. *Ever smoked 100 cigarettes in lifetime and now smoke every day or some days. All racial groups are exclusive of individuals identifying as Hispanic beginning in 1990. All estimates are age adjusted. Due to changes in National Health Interview Survey (NHIS) survey design, estimates from 2019 onward are not directly comparable to prior years and are separated from the trend line.

Sources: Adult cigarette smoking prevalence 1965-2018, Health United States: 2019; NHIS 1990-2021.


@2023, American Cancer Society, Inc., Surveillance and Health Equity Science



Menthol flavored cigarettes are a BIG PROBLEM

By Race and Ethnicity^d:

Current menthol cigarette smoking ranged from nearly 26 in 100 among Non-Hispanic (NH) White adults to nearly 84 in 100 among NH Black adults.










Menthol flavored cigarettes are a BIG PROBLEM

By Race and Ethnicity^d:

Current menthol cigarette smoking ranged from nearly 26 in 100 among Non-Hispanic (NH) White adults to nearly 84 in 100 among NH Black adults.





- Menthol cigarettes and flavors in cigars make it easier for kids to start smoking and harder for people to quit.
- Due in large part to tobacco industry marketing, over 80% of Black Americans who smoke use menthol cigarettes.


ALA 2024 State of Tobacco Control Report



TOBACCO PRODUCT USE AMONG ADULTS— United States, 2022

2022 National Health Interview Survey (NHIS) Highlights











2022 National Health Interview Survey (NHIS) Highlights




Tobacco Product Use – Cigarettes

Cigarettes were the most commonly used tobacco product among adults in 2022. As shown below, prevalence of cigarette smoking was higher in certain population groups.













2022 National Health Interview Survey (NHIS) Highlights




By Disability Statuse:

About 19 in 100 adults with a disability smoked cigarettes compared with 11 in 100 adults without a disability.

Adults with a disability

Adults without a disability







2022 National Health Interview Survey (NHIS) Highlights




By Disability Statuse:

About 19 in 100 adults with a disability smoked cigarettes compared with 11 in 100 adults without a disability.


Adults with a disability

Adults without a disability




By Current Generalized Anxiety Disorder (GAD)^f:

Current cigarette smoking ranged from $10 \, \text{in} \, 100$ among adults with no or minimal GAD to $27 \, \text{in} \, 100$ among adults with severe GAD.



By Current Depression^g:

Current cigarette smoking ranged from 10 in 100 among adults with no or minimal depression to 27 in 100 among adults with severe depression.





TOBACCO PRODUCT USE AMONG ADULTS— United States, 2022

2022 National Health Interview Survey (NHIS) Highlights




By Disability Statuse:

About 19 in 100 adults with a disability smoked cigarettes compared with 11 in 100 adults without a disability.


Adults with a disability

Adults without a disability




By Current Generalized Anxiety Disorder (GAD)^f:

Current cigarette smoking ranged from 10 in 100 among adults with no or minimal GAD to 27 in 100 among adults with severe GAD.



By Current Depression[§]:

Current cigarette smoking ranged from 10 in 100 among adults with no or minimal depression to 27 in 100 among adults with severe depression.



Cigarettes are disproportionately consumed by vulnerable populations to medicate emotional pain and distress.





IndianaReport Card



Tobacco Prevention and Control Program Funding: **Tobacco Taxes:**

Smokefree Air:

Access to Cessation Services:

Flavored Tobacco Products:

F











ALA 2024 State of Tobacco Control: Indiana




🖒 State Facts:	
Health Care Costs Due to Smoking:	\$2,930,404,456
Adult Smoking Rate:	16.2%
High School Smoking Rate:	4.2%
High School Tobacco Use Rate:	N/A
Middle School Smoking Rate:	1.9%
Smoking Attributable Deaths:	11,070





RADON FACT SHEET FOR INDIANA







RADON FACT SHEET FOR INDIANA




Red= High Potential for radon in the soil.

Orange= Moderate Potential for radon in the soil





RADON FACT SHEET FOR INDIANA



Red= High Potential for radon in the soil.


Orange= Moderate Potential for radon in the soil


Nearly 1 out of 3 homes in Indiana have high radon levels





RADON FACT SHEET FOR INDIANA








Zone 1

Zone 2

US News and World Report: Indiana








US News and World Report: Indiana








US News and World Report: Indiana









2024

Report Cards v

Report Card: Indiana
















Lung Cancer Screening Rates are VERY LOW

This compares to 65-75% screening rates for colon and breast cancer, respectively

State Ranking by High-Risk Screening Rate






Source: American Lung Association - 2023 State of Lung Cancer: https://www.lung.org/research/state-of-lung-cancer/states/indiana



Therapeutic Advances

- Immunotherapy prior to and/or after surgery for NSCLC
- Molecularly targeted therapy after surgery for early-stage NSCLC
- Molecularly targeted therapy after chemo plus radiation for stage III NSCLC
- Immunotherapy after chemo plus radiation for limited stage SCLC
- New immunotherapy combinations and antibody drug conjugates on the way
- Next generation targeted therapies look promising








CA: A Cancer Journal for Clinicians, Volume: 70, Issue: 1, Pages: 7-30;2020



Cancer-death projections by 2040



Rahib L et al, JAMA Network 2021;4(4):e214708







In summary,

- We are making transformational progress in the war against lung cancer
 - Prevention
 - Early Detection
 - Therapeutics
 - Advocacy
- NOW is the time to accelerate all these efforts.
 - We must avoid complacency and satisfaction with current progress









 While We are making progress, thousands of Hoosiers are still dying every year from lung cancer





- While We are making progress, thousands of Hoosiers are still dying every year from lung cancer
 - Let us resolve not to forget.





- While We are making progress, thousands of Hoosiers are still dying every year from lung cancer
 - Let us resolve not to forget.
 - This is a shared obligation and anyone who bears witness can and should do something about it.





- While We are making progress, thousands of Hoosiers are still dying every year from lung cancer
 - Let us resolve not to forget.
 - This is a shared obligation and anyone who bears witness can and should do something about it.
 - ❖ WE remain committed and not just interested.





- While We are making progress, thousands of Hoosiers are still dying every year from lung cancer
 - Let us resolve not to forget.
 - This is a shared obligation and anyone who bears witness can and should do something about it.
 - **WE** remain committed and not just interested.
 - ❖ While the mission is difficult, WE have the capacity to do it!



Thank you for attending



"Every time someone...acts to improve the lot of others...they send forth a tiny ripple of hope, and crossing each other from a million different centers of energy and daring, those ripples build a current that can sweep down the mightiest walls..."

~Paraphrasing RFK (italicized words are substitutions)

